<DOC>
	<DOCNO>NCT00139581</DOCNO>
	<brief_summary>This study conduct United States . To investigate relative efficacy pimecrolimus cream 1 % applied twice daily ( b.i.d . ) versus daily ( o.d . ) prevent progression disease `` relapse '' .</brief_summary>
	<brief_title>Comparison Pimecrolimus Cream 1 % Twice-Daily Once-Daily Dosing Management Atopic Dermatitis Pediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion Screening/RunIn Period age &gt; = 2 year age &lt; =17 year age IGA score 2 , 3 , 4 ( mild , moderate , severe AD ) affect &gt; 5 % TBSA outpatients Screening/RunIn period subject applied topical therapy ( e.g . tar , topical corticosteroid ) within 2 week prior Screening subject receive phototherapy ( e.g . UVB , PUVA , Narrow Band ) within 4 week Screening subject receive systemic immunosuppressant subject receive systemic steroid female pregnant breastfeeding , plan become pregnant study subject immunocompromised ( e.g . lymphoma , AIDS , WiskottAldrich syndrome ) history malignancy ( include basal cell carcinoma , squamous cell carcinoma , melanoma ) subject open skin infection ( bacterial , viral fungal ) application site . subject HSV ( common cold sore ) allow participate study ( application site ) . subject head lice scabies subject present clinical condition AD may interfere evaluation ( e.g. , generalized erythroderma , acne , Netherton 's Syndrome , psoriasis ) subject require systemic therapy treatment atopic dermatitis subject poor clinical response tacrolimus ointment ( ProtopicÂ® ) pimecrolimus cream 1 % subject use experimental investigational drug therapy within 6 week prior Screening subject intend use experimental investigational drug therapy course study subject know hypersensitivity pimecrolimus 1 % relate drug ( see Investigator 's Brochure ) subject noncompliant general medical treatment , know miss appointment , n't intend comply protocol duration study drug abuse , mental dysfunction , factor limit subject 's ability cooperate fully studyrelated procedure subject know unreliable may unable complete study condition prior/present treatment would render subject ineligible study Inclusion criterion Doubleblind Maintenance treatment period Achieve complete remission active disease ( sign symptom AD ) without incidence `` relapse '' end 6week RunIn period ( may earlier ) ; achieve `` disease improvement '' ( decrease IGA score 1 full point confirm investigator ) without incidence relapse end 6week RunIn period Exclusion criterion Doubleblind Maintenance treatment period subject experience `` relapse '' RunIn period subject apply topical corticosteroid alternative additional therapy treatment AD RunIn period subject active skin infection ( bacterial , viral fungal ) except common cold sore ( HSV ) application site subject fail record study medication use ( non use ) dose regimen RunIn period subject fail apply open label study drug twice daily `` disease remission '' end 6 week RunIn period subject fail record concomitant medication RunIn period failure return openlabel study drug ( use , partially use , unused tube ) time doubleblind study drug dispense . In order avoid medication error , open label study drug must return site start Maintenance period</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Atopic dermatitis , child , infant , pimecrolimus , bid , od</keyword>
</DOC>